Evidence map›Paper›PMID 38251379›Full record

ArticlePathogens (Basel, Switzerland)2024

Myxoma Virus Combination Therapy Enhances Lenalidomide and Bortezomib Treatments for Multiple Myeloma.

Alpay Yeşilaltay, Dilek Muz, Berna Erdal, Türker Bilgen, Bahadır Batar, Burhan Turgut, Birol Topçu, Bahar Yılmaz, Burcu Altındağ Avcı

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathogens (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Alpay YeşilaltayDepartment of Hematology, Faculty of Medicine, Başkent University Istanbul, Istanbul 34662, Türkiye.
Dilek MuzDepartment of Virology, Faculty of Veterinary, Tekirdağ Namık Kemal University, Tekirdag 59030, Türkiye.ORCID 0000-0001-9358-8103
Berna ErdalDepartment of Medical Microbiology, Faculty of Medicine, Tekirdağ Namık Kemal University, Tekirdag 59030, Türkiye.ORCID 0000-0003-3375-7926
Türker BilgenDepartment of Nutrition and Dietetics, Faculty of Health Sciences, Tekirdağ Namık Kemal University, Tekirdag 59030, Türkiye.
Bahadır BatarDepartment of Medical Biology, Faculty of Medicine, Tekirdağ Namık Kemal University, Tekirdag 59030, Türkiye.
Burhan TurgutDepartment of Hematology, Faculty of Medicine, Tekirdağ Namık Kemal University, Tekirdag 59030, Türkiye.
Birol TopçuDepartment of Biostatistics, Faculty of Medicine, Tekirdağ Namık Kemal University, Tekirdag 59030, Türkiye.
Bahar YılmazDepartment of Tumor Biology and Immunology, Institute of Health Sciences, Tekirdağ Namık Kemal University, Tekirdag 59030, Türkiye.
Burcu Altındağ AvcıDepartment of Hematology, Faculty of Medicine, Tekirdağ Namık Kemal University, Tekirdag 59030, Türkiye.
Tekirdağ Namık Kemal University · TRBaşkent University · TR

Funding

Scientific and Technological Research Council of Turkey 119S435
6 · The paper itself

Abstract

This study aimed to explore the effectiveness and safety of

Indexed as

ApoptosisBortezomibLenalidomideMultiple MyelomaMyxoma virusOncolytic VirotherapyAntineoplastic AgentsCell Line, TumorCell SurvivalCombined Modality TherapyHumansMaleThalidomideAntineoplastic AgentsBortezomibLenalidomideThalidomidebortezomiblenalidomidemultiple myelomamyxoma virusoncolytic virus

Identifiers

PMID38251379
PMCPMC10820570
OpenAlexW4390831099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.